Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk factors for low vancomycin trough concentrations in adults with augmented renal clearance
ChiCTR2500101565Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Apr 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vancomycin in bacterial disease (2 arms), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Serum steady-state trough concentration of vancomycin. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
vancomycin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on ChiCTR2500101565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101565.